世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

強直性脊椎炎治療薬の世界市場成長 2024-2030


Global Ankylosing Spondylitis Medication Market Growth 2024-2030

LPI(LPインフォメーション)の最新調査によると、強直性脊椎炎治療薬の世界市場規模は2023年に5億8,690万米ドルとなった。下流市場での需要拡大に伴い、強直性脊椎炎治療薬は2030年までに1億9,960万米ドルの再調... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年10月25日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
161 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、強直性脊椎炎治療薬の世界市場規模は2023年に5億8,690万米ドルとなった。下流市場での需要拡大に伴い、強直性脊椎炎治療薬は2030年までに1億9,960万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは9.3%である。
この調査レポートは、世界の強直性脊椎炎治療薬市場の成長可能性を明らかにしています。強直性脊椎炎治療薬は今後の市場でも安定した成長が期待される。しかし、強直性脊椎炎治療薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。市場関係者は、研究開発への投資、戦略的パートナーシップの構築、消費者の嗜好の変化に合わせた製品提供など、強直性脊椎炎治療薬市場がもたらす大きなチャンスを活かす必要がある。
強直性脊椎炎治療薬は、強直性脊椎炎を緩和または治療するために使用される医薬品である。
世界の医薬品市場は、2022年には1475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造部門の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。
主な特徴
強直性脊椎炎治療薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、強直性脊椎炎治療薬市場の現在の規模と成長の概要を提供します。過去のデータ、タイプ別(非ステロイド性抗炎症薬(NSAIDs)、副腎皮質ステロイド薬など)の市場区分、地域別内訳などが含まれます。
市場の促進要因と課題:当レポートでは、政府規制、環境問題、技術進歩、消費者の嗜好の変化など、強直性脊椎炎治療薬市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も浮き彫りにすることができます。
競合情勢:この調査レポートは、強直性脊椎炎治療薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。
技術開発:調査レポートは、強直性脊椎炎治療薬業界における最新の技術開発について掘り下げることができます。これには、強直性脊椎炎治療薬技術の進歩、強直性脊椎炎治療薬の新規参入、強直性脊椎炎治療薬の新規投資、強直性脊椎炎治療薬の将来を形作るその他の技術革新が含まれます。
川下の事業者の好み:本レポートは、強直性脊椎炎治療薬市場における顧客の購買行動と採用傾向に光を当てることができます。顧客の購買決定、強直性脊椎炎治療薬製品の嗜好に影響を与える要因も含まれる。
政府の政策とインセンティブ調査レポートは、政府の政策とインセンティブが強直性脊椎炎治療薬市場に与える影響を分析します。これには、規制の枠組み、補助金、税制優遇措置、その他強直性脊椎炎治療薬市場の促進を目的とした施策の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性についても評価します。
環境への影響と持続可能性強直性脊椎炎治療薬市場の環境への影響と持続可能性の側面を評価します。
市場予測と将来展望:実施した分析に基づき、調査レポートは強直性脊椎炎治療薬産業の市場予測と展望を提供します。これには、市場規模、成長率、地域別動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、強直性脊椎炎治療薬市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
強直性脊椎炎治療薬市場はタイプ別と用途別に分類される。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
非ステロイド性抗炎症薬(NSAIDs)
コルチコステロイド
疾患修飾性抗リウマチ薬(DMARDs)
生物学的製剤(TNF遮断薬)
スルファサラジン
メトトレキサート
その他
用途別セグメント
病院
専門クリニック
本レポートは地域別にも市場を分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ファイザー
UCBバイオファーマ
ヘテロ・バイオファーマ
アムジェン
カディラ・ファーマシューティカルズ
トレント・ファーマシューティカルズ
シプラ
エムキュア・ファーマシューティカルズ
ベーリンガーインゲルハイム
浙江久順製薬
バイオキャド
アッヴィ
マイセナックス・バイオテック
セルトリオン
ギリアド・サイエンシズ
江蘇恒瑞医薬有限公司
イザナ・バイオサイエンス
蘇州ゼルジェン・バイオファーマシューティカルズ
イルトゥーファーマ
キネバントサイエンシズ
Qyunsセラピューティクス
アケソ・バイオファーマ
ニンバス・セラピューティクス
エンゼン・バイオサイエンシズ
エクスブレイン・バイオファーマ
ダイス分子
MSD
本レポートで扱う主な質問
世界の強直性脊椎炎治療薬市場の10年見通しは?
世界および地域別に、強直性脊椎炎治療薬市場の成長を促進する要因は何か?
市場別、地域別に最も急成長する技術は何か?
強直性脊椎炎治療薬の市場機会は最終市場規模によってどのように異なるのか?
強直性脊椎炎治療薬のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ankylosing Spondylitis Medication Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ankylosing Spondylitis Medication by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ankylosing Spondylitis Medication by Country/Region, 2019, 2023 & 2030
2.2 Ankylosing Spondylitis Medication Segment by Type
2.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.2.2 Corticosteroids
2.2.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
2.2.4 Biologics (TNF-blocking Agents)
2.2.5 Sulfasalazine
2.2.6 Methotrexate
2.2.7 Others
2.3 Ankylosing Spondylitis Medication Sales by Type
2.3.1 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2019-2024)
2.3.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ankylosing Spondylitis Medication Sale Price by Type (2019-2024)
2.4 Ankylosing Spondylitis Medication Segment by Application
2.4.1 Hospital
2.4.2 Specialist Clinic
2.5 Ankylosing Spondylitis Medication Sales by Application
2.5.1 Global Ankylosing Spondylitis Medication Sale Market Share by Application (2019-2024)
2.5.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ankylosing Spondylitis Medication Sale Price by Application (2019-2024)
3 Global Ankylosing Spondylitis Medication by Company
3.1 Global Ankylosing Spondylitis Medication Breakdown Data by Company
3.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Company (2019-2024)
3.1.2 Global Ankylosing Spondylitis Medication Sales Market Share by Company (2019-2024)
3.2 Global Ankylosing Spondylitis Medication Annual Revenue by Company (2019-2024)
3.2.1 Global Ankylosing Spondylitis Medication Revenue by Company (2019-2024)
3.2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Company (2019-2024)
3.3 Global Ankylosing Spondylitis Medication Sale Price by Company
3.4 Key Manufacturers Ankylosing Spondylitis Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ankylosing Spondylitis Medication Product Location Distribution
3.4.2 Players Ankylosing Spondylitis Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ankylosing Spondylitis Medication by Geographic Region
4.1 World Historic Ankylosing Spondylitis Medication Market Size by Geographic Region (2019-2024)
4.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ankylosing Spondylitis Medication Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ankylosing Spondylitis Medication Market Size by Country/Region (2019-2024)
4.2.1 Global Ankylosing Spondylitis Medication Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ankylosing Spondylitis Medication Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ankylosing Spondylitis Medication Sales Growth
4.4 APAC Ankylosing Spondylitis Medication Sales Growth
4.5 Europe Ankylosing Spondylitis Medication Sales Growth
4.6 Middle East & Africa Ankylosing Spondylitis Medication Sales Growth
5 Americas
5.1 Americas Ankylosing Spondylitis Medication Sales by Country
5.1.1 Americas Ankylosing Spondylitis Medication Sales by Country (2019-2024)
5.1.2 Americas Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
5.2 Americas Ankylosing Spondylitis Medication Sales by Type
5.3 Americas Ankylosing Spondylitis Medication Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ankylosing Spondylitis Medication Sales by Region
6.1.1 APAC Ankylosing Spondylitis Medication Sales by Region (2019-2024)
6.1.2 APAC Ankylosing Spondylitis Medication Revenue by Region (2019-2024)
6.2 APAC Ankylosing Spondylitis Medication Sales by Type
6.3 APAC Ankylosing Spondylitis Medication Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ankylosing Spondylitis Medication by Country
7.1.1 Europe Ankylosing Spondylitis Medication Sales by Country (2019-2024)
7.1.2 Europe Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
7.2 Europe Ankylosing Spondylitis Medication Sales by Type
7.3 Europe Ankylosing Spondylitis Medication Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ankylosing Spondylitis Medication by Country
8.1.1 Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
8.2 Middle East & Africa Ankylosing Spondylitis Medication Sales by Type
8.3 Middle East & Africa Ankylosing Spondylitis Medication Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ankylosing Spondylitis Medication
10.3 Manufacturing Process Analysis of Ankylosing Spondylitis Medication
10.4 Industry Chain Structure of Ankylosing Spondylitis Medication
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ankylosing Spondylitis Medication Distributors
11.3 Ankylosing Spondylitis Medication Customer
12 World Forecast Review for Ankylosing Spondylitis Medication by Geographic Region
12.1 Global Ankylosing Spondylitis Medication Market Size Forecast by Region
12.1.1 Global Ankylosing Spondylitis Medication Forecast by Region (2025-2030)
12.1.2 Global Ankylosing Spondylitis Medication Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ankylosing Spondylitis Medication Forecast by Type
12.7 Global Ankylosing Spondylitis Medication Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 UCB Biopharma
13.2.1 UCB Biopharma Company Information
13.2.2 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 UCB Biopharma Main Business Overview
13.2.5 UCB Biopharma Latest Developments
13.3 Hetero Biopharma
13.3.1 Hetero Biopharma Company Information
13.3.2 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Hetero Biopharma Main Business Overview
13.3.5 Hetero Biopharma Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Cadila Pharmaceuticals
13.5.1 Cadila Pharmaceuticals Company Information
13.5.2 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Cadila Pharmaceuticals Main Business Overview
13.5.5 Cadila Pharmaceuticals Latest Developments
13.6 Torrent Pharmaceuticals
13.6.1 Torrent Pharmaceuticals Company Information
13.6.2 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Torrent Pharmaceuticals Main Business Overview
13.6.5 Torrent Pharmaceuticals Latest Developments
13.7 Cipla
13.7.1 Cipla Company Information
13.7.2 Cipla Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.7.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Cipla Main Business Overview
13.7.5 Cipla Latest Developments
13.8 Emcure Pharmaceuticals
13.8.1 Emcure Pharmaceuticals Company Information
13.8.2 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Emcure Pharmaceuticals Main Business Overview
13.8.5 Emcure Pharmaceuticals Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Zhejiang Hisun Pharmaceuticals
13.10.1 Zhejiang Hisun Pharmaceuticals Company Information
13.10.2 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Zhejiang Hisun Pharmaceuticals Main Business Overview
13.10.5 Zhejiang Hisun Pharmaceuticals Latest Developments
13.11 Biocad
13.11.1 Biocad Company Information
13.11.2 Biocad Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Biocad Main Business Overview
13.11.5 Biocad Latest Developments
13.12 AbbVie
13.12.1 AbbVie Company Information
13.12.2 AbbVie Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 AbbVie Main Business Overview
13.12.5 AbbVie Latest Developments
13.13 Mycenax Biotech
13.13.1 Mycenax Biotech Company Information
13.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Mycenax Biotech Main Business Overview
13.13.5 Mycenax Biotech Latest Developments
13.14 Celltrion
13.14.1 Celltrion Company Information
13.14.2 Celltrion Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Celltrion Main Business Overview
13.14.5 Celltrion Latest Developments
13.15 Gilead Sciences
13.15.1 Gilead Sciences Company Information
13.15.2 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Gilead Sciences Main Business Overview
13.15.5 Gilead Sciences Latest Developments
13.16 Jiangsu HengRui Medicine Co., Ltd.
13.16.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.16.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
13.17 Izana Bioscience
13.17.1 Izana Bioscience Company Information
13.17.2 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Izana Bioscience Main Business Overview
13.17.5 Izana Bioscience Latest Developments
13.18 Suzhou Zelgen Biopharmaceuticals
13.18.1 Suzhou Zelgen Biopharmaceuticals Company Information
13.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
13.18.5 Suzhou Zelgen Biopharmaceuticals Latest Developments
13.19 Iltoo Pharma
13.19.1 Iltoo Pharma Company Information
13.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Iltoo Pharma Main Business Overview
13.19.5 Iltoo Pharma Latest Developments
13.20 Kinevant Sciences
13.20.1 Kinevant Sciences Company Information
13.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Kinevant Sciences Main Business Overview
13.20.5 Kinevant Sciences Latest Developments
13.21 Qyuns Therapeutics
13.21.1 Qyuns Therapeutics Company Information
13.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Qyuns Therapeutics Main Business Overview
13.21.5 Qyuns Therapeutics Latest Developments
13.22 Akeso Biopharma
13.22.1 Akeso Biopharma Company Information
13.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Akeso Biopharma Main Business Overview
13.22.5 Akeso Biopharma Latest Developments
13.23 Nimbus Therapeutics
13.23.1 Nimbus Therapeutics Company Information
13.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Nimbus Therapeutics Main Business Overview
13.23.5 Nimbus Therapeutics Latest Developments
13.24 Enzene Biosciences
13.24.1 Enzene Biosciences Company Information
13.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 Enzene Biosciences Main Business Overview
13.24.5 Enzene Biosciences Latest Developments
13.25 Xbrane Biopharma
13.25.1 Xbrane Biopharma Company Information
13.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.25.4 Xbrane Biopharma Main Business Overview
13.25.5 Xbrane Biopharma Latest Developments
13.26 Dice molecules
13.26.1 Dice molecules Company Information
13.26.2 Dice molecules Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.26.4 Dice molecules Main Business Overview
13.26.5 Dice molecules Latest Developments
13.27 MSD
13.27.1 MSD Company Information
13.27.2 MSD Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.27.3 MSD Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.27.4 MSD Main Business Overview
13.27.5 MSD Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Ankylosing Spondylitis Medication market size was valued at US$ 5869.5 million in 2023. With growing demand in downstream market, the Ankylosing Spondylitis Medication is forecast to a readjusted size of US$ 10960 million by 2030 with a CAGR of 9.3% during review period.
The research report highlights the growth potential of the global Ankylosing Spondylitis Medication market. Ankylosing Spondylitis Medication are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Ankylosing Spondylitis Medication. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Ankylosing Spondylitis Medication market.
Ankylosing Spondylitis Medication is a drug used to relieve or treat ankylosing spondylitis.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Ankylosing Spondylitis Medication market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Ankylosing Spondylitis Medication market. It may include historical data, market segmentation by Type (e.g., Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Ankylosing Spondylitis Medication market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Ankylosing Spondylitis Medication market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Ankylosing Spondylitis Medication industry. This include advancements in Ankylosing Spondylitis Medication technology, Ankylosing Spondylitis Medication new entrants, Ankylosing Spondylitis Medication new investment, and other innovations that are shaping the future of Ankylosing Spondylitis Medication.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Ankylosing Spondylitis Medication market. It includes factors influencing customer ' purchasing decisions, preferences for Ankylosing Spondylitis Medication product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Ankylosing Spondylitis Medication market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Ankylosing Spondylitis Medication market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Ankylosing Spondylitis Medication market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Ankylosing Spondylitis Medication industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Ankylosing Spondylitis Medication market.
Market Segmentation:
Ankylosing Spondylitis Medication market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologics (TNF-blocking Agents)
Sulfasalazine
Methotrexate
Others
Segmentation by application
Hospital
Specialist Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
UCB Biopharma
Hetero Biopharma
Amgen
Cadila Pharmaceuticals
Torrent Pharmaceuticals
Cipla
Emcure Pharmaceuticals
Boehringer Ingelheim
Zhejiang Hisun Pharmaceuticals
Biocad
AbbVie
Mycenax Biotech
Celltrion
Gilead Sciences
Jiangsu HengRui Medicine Co., Ltd.
Izana Bioscience
Suzhou Zelgen Biopharmaceuticals
Iltoo Pharma
Kinevant Sciences
Qyuns Therapeutics
Akeso Biopharma
Nimbus Therapeutics
Enzene Biosciences
Xbrane Biopharma
Dice molecules
MSD
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ankylosing Spondylitis Medication market?
What factors are driving Ankylosing Spondylitis Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ankylosing Spondylitis Medication market opportunities vary by end market size?
How does Ankylosing Spondylitis Medication break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ankylosing Spondylitis Medication Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ankylosing Spondylitis Medication by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ankylosing Spondylitis Medication by Country/Region, 2019, 2023 & 2030
2.2 Ankylosing Spondylitis Medication Segment by Type
2.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.2.2 Corticosteroids
2.2.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
2.2.4 Biologics (TNF-blocking Agents)
2.2.5 Sulfasalazine
2.2.6 Methotrexate
2.2.7 Others
2.3 Ankylosing Spondylitis Medication Sales by Type
2.3.1 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2019-2024)
2.3.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ankylosing Spondylitis Medication Sale Price by Type (2019-2024)
2.4 Ankylosing Spondylitis Medication Segment by Application
2.4.1 Hospital
2.4.2 Specialist Clinic
2.5 Ankylosing Spondylitis Medication Sales by Application
2.5.1 Global Ankylosing Spondylitis Medication Sale Market Share by Application (2019-2024)
2.5.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ankylosing Spondylitis Medication Sale Price by Application (2019-2024)
3 Global Ankylosing Spondylitis Medication by Company
3.1 Global Ankylosing Spondylitis Medication Breakdown Data by Company
3.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Company (2019-2024)
3.1.2 Global Ankylosing Spondylitis Medication Sales Market Share by Company (2019-2024)
3.2 Global Ankylosing Spondylitis Medication Annual Revenue by Company (2019-2024)
3.2.1 Global Ankylosing Spondylitis Medication Revenue by Company (2019-2024)
3.2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Company (2019-2024)
3.3 Global Ankylosing Spondylitis Medication Sale Price by Company
3.4 Key Manufacturers Ankylosing Spondylitis Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ankylosing Spondylitis Medication Product Location Distribution
3.4.2 Players Ankylosing Spondylitis Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ankylosing Spondylitis Medication by Geographic Region
4.1 World Historic Ankylosing Spondylitis Medication Market Size by Geographic Region (2019-2024)
4.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ankylosing Spondylitis Medication Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ankylosing Spondylitis Medication Market Size by Country/Region (2019-2024)
4.2.1 Global Ankylosing Spondylitis Medication Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ankylosing Spondylitis Medication Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ankylosing Spondylitis Medication Sales Growth
4.4 APAC Ankylosing Spondylitis Medication Sales Growth
4.5 Europe Ankylosing Spondylitis Medication Sales Growth
4.6 Middle East & Africa Ankylosing Spondylitis Medication Sales Growth
5 Americas
5.1 Americas Ankylosing Spondylitis Medication Sales by Country
5.1.1 Americas Ankylosing Spondylitis Medication Sales by Country (2019-2024)
5.1.2 Americas Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
5.2 Americas Ankylosing Spondylitis Medication Sales by Type
5.3 Americas Ankylosing Spondylitis Medication Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ankylosing Spondylitis Medication Sales by Region
6.1.1 APAC Ankylosing Spondylitis Medication Sales by Region (2019-2024)
6.1.2 APAC Ankylosing Spondylitis Medication Revenue by Region (2019-2024)
6.2 APAC Ankylosing Spondylitis Medication Sales by Type
6.3 APAC Ankylosing Spondylitis Medication Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ankylosing Spondylitis Medication by Country
7.1.1 Europe Ankylosing Spondylitis Medication Sales by Country (2019-2024)
7.1.2 Europe Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
7.2 Europe Ankylosing Spondylitis Medication Sales by Type
7.3 Europe Ankylosing Spondylitis Medication Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ankylosing Spondylitis Medication by Country
8.1.1 Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2019-2024)
8.2 Middle East & Africa Ankylosing Spondylitis Medication Sales by Type
8.3 Middle East & Africa Ankylosing Spondylitis Medication Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ankylosing Spondylitis Medication
10.3 Manufacturing Process Analysis of Ankylosing Spondylitis Medication
10.4 Industry Chain Structure of Ankylosing Spondylitis Medication
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ankylosing Spondylitis Medication Distributors
11.3 Ankylosing Spondylitis Medication Customer
12 World Forecast Review for Ankylosing Spondylitis Medication by Geographic Region
12.1 Global Ankylosing Spondylitis Medication Market Size Forecast by Region
12.1.1 Global Ankylosing Spondylitis Medication Forecast by Region (2025-2030)
12.1.2 Global Ankylosing Spondylitis Medication Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ankylosing Spondylitis Medication Forecast by Type
12.7 Global Ankylosing Spondylitis Medication Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 UCB Biopharma
13.2.1 UCB Biopharma Company Information
13.2.2 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 UCB Biopharma Main Business Overview
13.2.5 UCB Biopharma Latest Developments
13.3 Hetero Biopharma
13.3.1 Hetero Biopharma Company Information
13.3.2 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Hetero Biopharma Main Business Overview
13.3.5 Hetero Biopharma Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Cadila Pharmaceuticals
13.5.1 Cadila Pharmaceuticals Company Information
13.5.2 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Cadila Pharmaceuticals Main Business Overview
13.5.5 Cadila Pharmaceuticals Latest Developments
13.6 Torrent Pharmaceuticals
13.6.1 Torrent Pharmaceuticals Company Information
13.6.2 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Torrent Pharmaceuticals Main Business Overview
13.6.5 Torrent Pharmaceuticals Latest Developments
13.7 Cipla
13.7.1 Cipla Company Information
13.7.2 Cipla Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.7.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Cipla Main Business Overview
13.7.5 Cipla Latest Developments
13.8 Emcure Pharmaceuticals
13.8.1 Emcure Pharmaceuticals Company Information
13.8.2 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Emcure Pharmaceuticals Main Business Overview
13.8.5 Emcure Pharmaceuticals Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Zhejiang Hisun Pharmaceuticals
13.10.1 Zhejiang Hisun Pharmaceuticals Company Information
13.10.2 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Zhejiang Hisun Pharmaceuticals Main Business Overview
13.10.5 Zhejiang Hisun Pharmaceuticals Latest Developments
13.11 Biocad
13.11.1 Biocad Company Information
13.11.2 Biocad Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Biocad Main Business Overview
13.11.5 Biocad Latest Developments
13.12 AbbVie
13.12.1 AbbVie Company Information
13.12.2 AbbVie Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 AbbVie Main Business Overview
13.12.5 AbbVie Latest Developments
13.13 Mycenax Biotech
13.13.1 Mycenax Biotech Company Information
13.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Mycenax Biotech Main Business Overview
13.13.5 Mycenax Biotech Latest Developments
13.14 Celltrion
13.14.1 Celltrion Company Information
13.14.2 Celltrion Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Celltrion Main Business Overview
13.14.5 Celltrion Latest Developments
13.15 Gilead Sciences
13.15.1 Gilead Sciences Company Information
13.15.2 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Gilead Sciences Main Business Overview
13.15.5 Gilead Sciences Latest Developments
13.16 Jiangsu HengRui Medicine Co., Ltd.
13.16.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.16.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
13.17 Izana Bioscience
13.17.1 Izana Bioscience Company Information
13.17.2 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Izana Bioscience Main Business Overview
13.17.5 Izana Bioscience Latest Developments
13.18 Suzhou Zelgen Biopharmaceuticals
13.18.1 Suzhou Zelgen Biopharmaceuticals Company Information
13.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
13.18.5 Suzhou Zelgen Biopharmaceuticals Latest Developments
13.19 Iltoo Pharma
13.19.1 Iltoo Pharma Company Information
13.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Iltoo Pharma Main Business Overview
13.19.5 Iltoo Pharma Latest Developments
13.20 Kinevant Sciences
13.20.1 Kinevant Sciences Company Information
13.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Kinevant Sciences Main Business Overview
13.20.5 Kinevant Sciences Latest Developments
13.21 Qyuns Therapeutics
13.21.1 Qyuns Therapeutics Company Information
13.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Qyuns Therapeutics Main Business Overview
13.21.5 Qyuns Therapeutics Latest Developments
13.22 Akeso Biopharma
13.22.1 Akeso Biopharma Company Information
13.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Akeso Biopharma Main Business Overview
13.22.5 Akeso Biopharma Latest Developments
13.23 Nimbus Therapeutics
13.23.1 Nimbus Therapeutics Company Information
13.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Nimbus Therapeutics Main Business Overview
13.23.5 Nimbus Therapeutics Latest Developments
13.24 Enzene Biosciences
13.24.1 Enzene Biosciences Company Information
13.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 Enzene Biosciences Main Business Overview
13.24.5 Enzene Biosciences Latest Developments
13.25 Xbrane Biopharma
13.25.1 Xbrane Biopharma Company Information
13.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.25.4 Xbrane Biopharma Main Business Overview
13.25.5 Xbrane Biopharma Latest Developments
13.26 Dice molecules
13.26.1 Dice molecules Company Information
13.26.2 Dice molecules Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.26.4 Dice molecules Main Business Overview
13.26.5 Dice molecules Latest Developments
13.27 MSD
13.27.1 MSD Company Information
13.27.2 MSD Ankylosing Spondylitis Medication Product Portfolios and Specifications
13.27.3 MSD Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.27.4 MSD Main Business Overview
13.27.5 MSD Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(medication)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る